Literature DB >> 2403836

Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study.

F Pandolfi1, T P Loughran, G Starkebaum, T Chisesi, T Barbui, W C Chan, J C Brouet, G De Rossi, R W McKenna, F Salsano.   

Abstract

Lymphoproliferative disease of granular lymphocytes (LDGL) is a recently recognized, relatively rare atypical lymphocytosis characterized by the presence of over 2000 lymphocytes with cytoplasmic azurophilic granules/mm3 in the peripheral blood. The clinical course is heterogeneous, varying from spontaneous regression to progressive, malignant disease. As a consequence, clinical intervention is not standardized. In a worldwide multicenter study, the authors observed 151 patients with LDGL for a mean follow-up time of 29 months. Forty-three patients were asymptomatic at the time of diagnosis. In the remaining cases, clinical symptoms included fever (41 cases), infections (58), neutropenia (47), anemia (17), and thrombocytopenia (12). In 69 cases, LDGL coexisted with an associated disease. Most patients had a nonprogressive clinical course despite the presence of severe symptoms. In 19 patients, death related to LDGL occurred within 48 months. The authors investigated which features at diagnosis were significantly associated with increased mortality. In the univariate analysis, lymph node and liver enlargement, fever at presentation, skin infiltration, a low (less than or equal to 5000/mm3) or high (greater than 20,000/mm3) peripheral leukocyte count, relatively low (less than or equal to 3000) or high (greater than 7000/mm3) absolute peripheral granular lymphocyte (GL) count, and a low (less than or equal to 15%) percentage of HNK-1-positive cells were found to be predictors of increased mortality. In the multivariate analysis, significant independent predictors were fever at diagnosis, a low (less than or equal to 15%) percentage of HNK-1-positive peripheral blood mononuclear cells (PBMC) and a relatively low (less than or equal to 3000) GL count. These results showed that about 25% of the patients with LDGL were diagnosed after a routine blood count and had no clinical symptoms. The remaining patients were symptomatic, with some experiencing a fatal clinical course. The author's analysis of the significant prognostic features of LDGL may help in understanding the heterogeneous nature of this syndrome.

Entities:  

Mesh:

Year:  1990        PMID: 2403836     DOI: 10.1002/1097-0142(19900115)65:2<341::aid-cncr2820650227>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

2.  Association of pure red cell aplasia with T large granular lymphocyte leukaemia.

Authors:  Y L Kwong; K F Wong
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

Review 3.  The pathogenesis and treatment of large granular lymphocyte leukemia.

Authors:  Steven Nathaniel Steinway; Francis LeBlanc; Thomas P Loughran
Journal:  Blood Rev       Date:  2014-03-07       Impact factor: 8.250

4.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

5.  Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases.

Authors:  Benoît Bareau; Jérôme Rey; Mohamed Hamidou; Jean Donadieu; Jeff Morcet; Oumedaly Reman; Nicolas Schleinitz; Olivier Tournilhac; Mikael Roussel; Thierry Fest; Thierry Lamy
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

6.  Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia.

Authors:  Tyler G Ketterl; David Wu; Jonathan R Fromm; Lorinda Soma; Ann E Dahlberg; Brent L Wood; Katherine Tarlock
Journal:  Bone Marrow Transplant       Date:  2017-12-21       Impact factor: 5.483

7.  Coexistent Felty's syndrome and palindromic rheumatism.

Authors:  R E Alvillar; L O'Grady; D Robbins
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

8.  Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells.

Authors:  Cristina Gattazzo; Antonella Teramo; Francesca Passeri; Elena De March; Samuela Carraro; Valentina Trimarco; Federica Frezzato; Tamara Berno; Gregorio Barilà; Veronica Martini; Francesco Piazza; Livio Trentin; Monica Facco; Gianpietro Semenzato; Renato Zambello
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

9.  Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).

Authors:  T P Loughran; L Zickl; T L Olson; V Wang; D Zhang; H L M Rajala; Z Hasanali; J M Bennett; H M Lazarus; M R Litzow; A M Evens; S Mustjoki; M S Tallman
Journal:  Leukemia       Date:  2014-09-13       Impact factor: 11.528

10.  CD20- and CD56-positive T-cell large granular lymphocyte leukemia in a human T-cell leukemia virus type 1 carrier.

Authors:  Sonoko Nakano-Akamatsu; Ryoichi Takahashi; Yukiko Sekioka; Yohei Hosokawa; Tohru Inaba
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.